Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 17/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4377805 | 0.92 | ALDH1A1 (0.45) | GSK3BHTT | |
| SCHEMBL2065426 | 0.91 | DRD4 (0.42) | GSK3B | |
| SCHEMBL2065496 | 0.90 | GRM5 (0.46) | GSK3B | |
| SCHEMBL2065105 | 0.90 | GSK3B (0.44) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL4768777 | 0.89 | GSK3B (0.38) | GSK3BCYP2D6 | |
| SCHEMBL2066088 | 0.88 | GSK3B (0.40) | GSK3BCYP2D6CYP3A4SCDSCD5 | |
| SCHEMBL2065099 | 0.88 | GSK3B (0.47) | GSK3BCYP2D6CYP3A4CYP1A2 | |
| SCHEMBL3401659 | 0.87 | GSK3B (0.39) | GSK3BCYP2D6CYP3A4SCDSCD5 | |
| SCHEMBL4381747 | 0.86 | KMT2A (0.40) | GSK3BCYP2D6 | |
| SCHEMBL4378741 | 0.86 | ALDH1A1 (0.44) | GSK3BCYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148364-B2 | Substituted bicyclic pyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-04-03 | — | — | US | claimed |
| EP-1957492-B1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI AVENTIS (FR) | 2010-11-10 | — | — | EP | claimed |
| US-20090036427-A1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | claimed |
| EP-1957492-A2 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | sanofi-aventis (FR) | 2008-08-20 | — | — | EP | claimed |
| EP-1790649-A1 | Substituted bicyclic pyrimidone derivatives | Sanofi-Aventis (FR) | 2007-05-30 | — | — | EP | claimed |
| WO-2007057790-A2 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2007-05-24 | — | — | WO | claimed |
| US-8148364-B2 | Substituted bicyclic pyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-04-03 | — | — | US | disclosed |
| EP-1957492-B1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI AVENTIS (FR) | 2010-11-10 | — | — | EP | disclosed |
| US-20090036427-A1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
| EP-1957492-A2 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | sanofi-aventis (FR) | 2008-08-20 | — | — | EP | disclosed |
| EP-1790649-A1 | Substituted bicyclic pyrimidone derivatives | Sanofi-Aventis (FR) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007057790-A2 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036427-A1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | GSK3B, GSK3A, PSEN1 | GSK3B 1/4885CYP2D6 1253/4885CYP3A4 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.